{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:05:10Z","timestamp":1787065510781,"version":"build-2736575974"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","funder":[{"DOI":"10.13039\/501100000191","name":"Kidney Foundation of Canada","doi-asserted-by":"crossref","award":["KHRG-919864"],"award-info":[{"award-number":["KHRG-919864"]}],"id":[{"id":"10.13039\/501100000191","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2025,6]]},"abstract":"\n Key Points<\/jats:title>\n \n \n \n Treatment with sodium-glucose cotransporter-2 inhibitor (SGLT-2i) provides kidney and cardiovascular protection in patients with advanced CKD.<\/jats:p>\n <\/jats:list-item>\n \n The glycosuric action of SGLT-2i is attenuated in advanced CKD resulting in no change in glycated hemoglobin and fewer volume depletion events.<\/jats:p>\n <\/jats:list-item>\n \n The use of SGLT-2i did not increase the incidence of AKI, urine infections, fractures, or treatment discontinuation due to adverse events.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n <\/jats:sec>\n \n Background<\/jats:title>\n \n The efficacy and safety of sodium-glucose cotransporter-2 inhibitor (SGLT-2i) in patients with advanced CKD, defined as an eGFR <30 ml\/min per 1.73 m\n 2<\/jats:sup>\n , has not been adequately studied.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n We conducted a systematic review and meta-analysis of phase 3 randomized controlled trials of SGLT-2i in adults. We searched the medical literature analysis and retrieval system online and excerpta medica database databases from inception to April 2024. The primary outcomes were composite kidney (worsening kidney function, kidney failure, and kidney or cardiovascular [CV] death) and CV (CV death or hospitalization for heart failure) outcomes. Secondary outcomes included other reported CV and kidney outcomes, eGFR slopes, mechanistic, and safety outcomes. The risk ratios (RR) were estimated using a random effects model. Interaction effects were estimated for treatment effect modification by baseline eGFR (<30 and \u226530 ml\/min per 1.73 m\n 2<\/jats:sup>\n ).\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of ten randomized controlled trials were included (total of 4800 patients with eGFR <30 ml\/min per 1.73 m\n 2<\/jats:sup>\n ). Participants were randomized to receive either placebo or an SGLT-2i. The use of SGLT-2i was associated with a lower incidence of the primary composite kidney outcome in patients with eGFR <30 ml\/min per 1.73 m\n 2<\/jats:sup>\n (RR, 0.79; 95% confidence interval [CI], 0.70 to 0.89) and \u226530 ml\/min per 1.73 m\n 2<\/jats:sup>\n (RR, 0.71; 95% CI, 0.64 to 0.79). The incidence of the primary CV outcome was numerically lower in the SGLT-2i arm in patients with eGFR <30 ml\/min per 1.73 m\n 2<\/jats:sup>\n (RR, 0.88; 95% CI, 0.71 to 1.10). In patients with eGFR \u226530 ml\/min per 1.73 m\n 2<\/jats:sup>\n , SGLT-2i use was associated with a lower incidence of the composite CV outcome (RR, 0.77; 95% CI, 0.71 to 0.83). However, there was no interaction between advanced CKD status and the effect of SGLT-2i on any of the primary or secondary outcomes. The incidence of adverse events was similar in both arms.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n SGLT-2i retain their kidney and CV protective effect in patients with advanced CKD, with no added safety concerns.<\/jats:p>\n <\/jats:sec>","DOI":"10.2215\/cjn.0000000693","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T18:11:02Z","timestamp":1743012662000},"page":"788-809","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with and without Advanced CKD"],"prefix":"10.2215","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4138-8390","authenticated-orcid":false,"given":"Elias John","family":"Elenjickal","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada"},{"name":"Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada"},{"name":"Division of Clinical and Translational Research, Department of Medicine, McGill University, Montreal, Quebec, Canada"},{"name":"Department of Nephrology, Christian Medical College, Vellore, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7797-8141","authenticated-orcid":false,"given":"Christoforos K.","family":"Travlos","sequence":"additional","affiliation":[{"name":"Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada"},{"name":"Division of Clinical and Translational Research, Department of Medicine, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1429-0788","authenticated-orcid":false,"given":"Judy","family":"Luu","sequence":"additional","affiliation":[{"name":"Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada"},{"name":"Division of Clinical and Translational Research, Department of Medicine, McGill University, Montreal, Quebec, Canada"},{"name":"Division of Cardiology, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4813-1919","authenticated-orcid":false,"given":"Serge","family":"Lemay","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada"},{"name":"Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada"},{"name":"Division of Clinical and Translational Research, Department of Medicine, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0519-3927","authenticated-orcid":false,"given":"Rita S.","family":"Suri","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada"},{"name":"Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada"},{"name":"Division of Clinical and Translational Research, Department of Medicine, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3368-247X","authenticated-orcid":false,"given":"Thomas A.","family":"Mavrakanas","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada"},{"name":"Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada"},{"name":"Division of Clinical and Translational Research, Department of Medicine, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"issue":"1","key":"B1-20250609","doi-asserted-by":"crossref","first-page":"15922","DOI":"10.1038\/s41598-023-42989-z","article-title":"SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: a systematic review and meta-analysis","volume":"13","author":"Mavrakanas","year":"2023","journal-title":"Sci Rep."},{"issue":"22","key":"B2-20250609","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med."},{"issue":"7","key":"B3-20250609","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med."},{"issue":"4","key":"B4-20250609","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med."},{"issue":"2","key":"B5-20250609","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"New Engl J Med."},{"issue":"21","key":"B6-20250609","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med."},{"issue":"15","key":"B7-20250609","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med."},{"issue":"16","key":"B8-20250609","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med."},{"issue":"2","key":"B9-20250609","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"New Engl J Med."},{"issue":"15","key":"B10-20250609","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"New Engl J Med."},{"issue":"24","key":"B11-20250609","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and Nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med."},{"key":"B12-20250609","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ."},{"issue":"9","key":"B13-20250609","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1681\/ASN.2021020167","article-title":"Effects of dapagliflozin in stage 4 chronic kidney disease","volume":"32","author":"Chertow","year":"2021","journal-title":"J Am Soc Nephrol."},{"issue":"12","key":"B14-20250609","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.2215\/CJN.10140620","article-title":"Effects of canagliflozin in patients with baseline eGFR <30 ml\/min per 1.73 m2: subgroup analysis of the randomized CREDENCE trial","volume":"15","author":"Bakris","year":"2020","journal-title":"Clin J Am Soc Nephrol."},{"issue":"15","key":"B15-20250609","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1161\/CIRCULATIONAHA.118.035901","article-title":"Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function","volume":"138","author":"Neuen","year":"2018","journal-title":"Circulation."},{"issue":"3","key":"B16-20250609","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials."},{"issue":"7","key":"B17-20250609","doi-asserted-by":"crossref","first-page":"e010247","DOI":"10.1136\/bmjopen-2015-010247","article-title":"Plea for routinely presenting prediction intervals in meta-analysis","volume":"6","author":"IntHout","year":"2016","journal-title":"BMJ Open."},{"key":"B18-20250609","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ."},{"issue":"7650","key":"B20-20250609","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ."},{"issue":"1","key":"B21-20250609","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res Synth Methods."},{"issue":"1","key":"B22-20250609","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S2213-8587(23)00321-2","article-title":"Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial","volume":"12","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"8","key":"B23-20250609","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1111\/dom.15112","article-title":"Kidney protection with canagliflozin: a combined analysis of the randomized CANVAS program and CREDENCE trials","volume":"25","author":"Sridhar","year":"2023","journal-title":"Diabetes Obes Metab."},{"issue":"5","key":"B24-20250609","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2215\/CJN.0000000000000414","article-title":"Sotagliflozin and kidney outcomes, kidney function, and albuminuria in type 2 diabetes and CKD: a secondary analysis of the SCORED trial","volume":"19","author":"Sridhar","year":"2024","journal-title":"Clin J Am Soc Nephrol."},{"issue":"4","key":"B25-20250609","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1161\/CIRCULATIONAHA.120.051685","article-title":"Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from EMPEROR-reduced","volume":"143","author":"Zannad","year":"2021","journal-title":"Circulation."},{"issue":"8","key":"B26-20250609","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/ejhf.2857","article-title":"Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from the EMPEROR-Preserved trial","volume":"25","author":"Sharma","year":"2023","journal-title":"Eur J Heart Fail."},{"issue":"12","key":"B27-20250609","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1111\/dom.14513","article-title":"Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment","volume":"23","author":"Cherney","year":"2021","journal-title":"Diabetes Obes Metab."},{"issue":"5","key":"B28-20250609","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","article-title":"Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Barnett","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"B29-20250609","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.kint.2017.06.017","article-title":"Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin","volume":"93","author":"Cherney","year":"2018","journal-title":"Kidney Int."},{"issue":"5","key":"B30-20250609","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.kint.2022.06.013","article-title":"Executive summary of the KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease: an update based on rapidly emerging new evidence","volume":"102","author":"Ross ing","year":"2022","journal-title":"Kidney Int."},{"issue":"3","key":"B31-20250609","doi-asserted-by":"crossref","first-page":"455","DOI":"10.34067\/KID.0007862021","article-title":"Prescribing patterns of sodium-glucose cotransporter-2 inhibitors in patients with CKD: a cross-sectional registry analysis","volume":"3","author":"Zhuo","year":"2022","journal-title":"Kidney360."},{"issue":"3","key":"B32-20250609","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00592-022-01989-7","article-title":"Effects of sodium-glucose co-transporter-2 inhibitors on kidney, cardiovascular, and safety outcomes in patients with advanced chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials","volume":"60","author":"Cao","year":"2023","journal-title":"Acta Diabetol."},{"issue":"9","key":"B33-20250609","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1681\/ASN.2019010007","article-title":"GFR slope as a surrogate end point for kidney disease progression in clinical trials: a meta-analysis of treatment effects of randomized controlled trials","volume":"30","author":"Inker","year":"2019","journal-title":"J Am Soc Nephrol."},{"issue":"11","key":"B34-20250609","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.120.045691","article-title":"Empagliflozin in heart failure: diuretic and cardiorenal effects","volume":"142","author":"Griffin","year":"2020","journal-title":"Circulation."},{"issue":"13","key":"B35-20250609","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med."},{"issue":"12","key":"B36-20250609","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/ki.2010.536","article-title":"Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts","volume":"79","author":"van der Velde","year":"2011","journal-title":"Kidney Int."},{"issue":"1","key":"B37-20250609","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41371-020-00393-4","article-title":"SGLT-2 inhibitors and nephroprotection: current evidence and future perspectives","volume":"35","author":"Piperidou","year":"2021","journal-title":"J Hum Hypertens."},{"issue":"3","key":"B38-20250609","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","article-title":"Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na(+)\/H(+) exchanger, lowering of cytosolic Na(+) and vasodilation","volume":"61","author":"Uthman","year":"2018","journal-title":"Diabetologia."},{"issue":"16","key":"B39-20250609","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1161\/CIRCULATIONAHA.117.030418","article-title":"Activation and inhibition of sodium-hydrogen exchanger is a mechanism that links the pathophysiology and treatment of diabetes mellitus with that of heart failure","volume":"136","author":"Packer","year":"2017","journal-title":"Circulation."},{"key":"B40-20250609","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1475-2840-13-28","article-title":"The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus","volume":"13","author":"Cherney","year":"2014","journal-title":"Cardiovasc Diabetol."},{"issue":"12","key":"B41-20250609","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/dom.12572","article-title":"Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes","volume":"17","author":"Chilton","year":"2015","journal-title":"Diabetes Obes Metab."},{"issue":"6","key":"B42-20250609","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1161\/HYPERTENSIONAHA.116.07703","article-title":"Impact of empagliflozin on blood pressure in patients with type 2 diabetes mellitus and hypertension by background antihypertensive medication","volume":"68","author":"Mancia","year":"2016","journal-title":"Hypertension."},{"issue":"18","key":"B43-20250609","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1161\/CIRCULATIONAHA.118.037076","article-title":"Twenty-four-hour blood pressure-lowering effect of a sodium-glucose cotransporter 2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: results from the randomized, placebo-controlled SACRA study","volume":"139","author":"Kario","year":"2019","journal-title":"Circulation."},{"issue":"10365","key":"B44-20250609","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","year":"2022","journal-title":"Lancet."}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000000693","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:42:42Z","timestamp":1786369362000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000000693"}},"subtitle":["Systematic Review and Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.0000000693","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]},"assertion":[{"value":"2024-11-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}